Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 10, 2009, Pages 723-729

  Mora, Jaume ^a   Cruz, Cheeu Ofelia ^a   Parareda, Andreu ^a   De Torres, Carmen ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Docetaxel; Ewing sarcoma; Gemcitabine; Relapsed refractory pediatric sarcomas

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GEMCITABINE; ONDANSETRON; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG ERUPTION; EWING SARCOMA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; OSTEOSARCOMA; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; SYNOVIAL SARCOMA; TREATMENT RESPONSE; WEIGHT GAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; OSTEOSARCOMA; OUTPATIENTS; REMISSION INDUCTION; SALVAGE THERAPY; SARCOMA; SARCOMA, EWING'S; SARCOMA, SYNOVIAL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 70349808172     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b2598c     Document Type: Article

References (24)

1. Ries LAG, Smith MA, Gurney JG, et al.. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No.99-4649. Bethesda, MD, 1999.
2. Bollard CM, Krance RA, Heslop HE. Hematopoietic Stem cell transplantation in pediatric oncology. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, USA: Lippincott Williams & Wilkins; 2006: 476-500.
3. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
4. Hensley ML, Maki R, Venkatraman E, et al.. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831.
5. Leu KM, Ostruszka LJ, Shewach D, et al.. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706-1712.
6. Bay JO, Ray-Coquard I, Fayette J, et al.. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. Int J Cancer. 2006;119:706-711.
7. Maki RG, Wathen JK, Patel SR, et al.. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas. J Clin Oncol. 2007;25:2755-2763.
8. Zwerdling T, Krailo M, Monteleone P, et al, Children's Oncology Group. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's Oncology Group. Cancer. 2006;106:1821-1828.
9. Reid JM, Qu W, Safgren SL, et al.. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol. 2004;22:2445-2451.
10. Bissery MC, Gué nard D, Gué ritte-Voegelein F, et al.. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845-4852.
11. Blaney SM, Seibel NL, O'Brien M, et al.. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997;15:1538-1543.
12. Seibel NL, Blaney SM, O'Brien M, et al.. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: A collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999;5:733-737.
13. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol. 2004;16: 120-125.
14. Stegmaier K, Wong JS, Ross KN, et al.. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007; 4:e122.
15. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12:1527-1531.
16. Rodriguez-Galindo C, Billups CA, Kun LE, et al.. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer. 2002;94: 561-569.
17. Barker LM, Pendergrass TW, Sanders JE, et al.. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354-4362.
18. Heinemann V, Xu YZ, Chubb S, et al.. Cellular elimination of 2', 2'-di.uorodeoxycytidine 5'-triphosphate: A mechanism of self-potentiation. Cancer Res. 1992;52:533-539.
19. Anderson PM, Wiseman GA, Erlandson L, et al.. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005;11:6895-6900.
20. Bergman AM, Pinedo HM, Talianidis I, et al.. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88:1963-1970.
21. Navid F, Willert JR, Carville BMc, et al.. Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults with Refractory Bone Sarcoma. Cancer. 2008; 113:419-425.
22. Whelan JS, McTiernan A, Kakouri E, et al.. London bone and soft tissue tumour service. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer. 2004;43:237-242.
23. Saylors RL, III, Stine KC, Sullivan J, et al.. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469. (Pubitemid 32730082)
24. Wagner LM, Crews KR, Iacono LC, et al.. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004;10: 840-848.